New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries

Questions? Call 800-624-6242

About | Ordering | New

LoginRegister

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

Free PDF Access

Sign in to download PDF book and chapters

Free Resources

Related Titles

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager Export the bibliographic data for this book in your chosen format
Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web.
Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book.
Reference Finder Paste in your own text to find books that relate to your topic.

Citation Manager

. "4. Comparison of Disease Burdens." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

Page
45


E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

TABLE 4.1 World Population Data

Region or Country	Population as of Mid-1984 (millions)	Crude Birth Rate (per 1,000 population)	Infant Mortality Rate (per 1,000 live births)	Percent Population Under Age 15	Percent Population Over Age 64	Urban Population (percent)
World^a	4,762	28	84	35	6	40
Less developed	3,596	32	94	38	4	32
Africa	531	45	119	45	3	29
Asia^b	2,662	30	91	38	4	25
Latin America^c	397	31	65	39	4	65
Oceania^d	5	41	89	43	3	18
More developed	1,116	16	19	23	12	71
Europe	491	14	15	22	13	72
North America^e	262	15	11	22	12	74
USSR	274	20	32	25	10	64
Australia, New Zealand	19	16	11	25	10	85
Japan	120	13	7	23	9	76
^aError in total population due to rounding. ^bJapan is excluded. China is included. ^cMexico, Central America, and South America are included. ^dAustralia and New Zealand are not included. ^eCanada and the United States are included. SOURCE: Population Reference Bureau, Inc. (1984).

Page
45

Front Matter (R1-R16)

1. Summary (1-18)

2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)

3. Overview of the Analytic Approach (30-43)

4. Comparison of Disease Burdens (44-62)

5. Predictions of Vaccine Development (63-75)

6. Assessing the Likely Utilization of New Vaccines (76-81)

7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)

8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)

9. Findings, Conclusions, and Recommendations (121-142)

Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)

Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)

Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)

Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)

Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)

Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)

Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)

Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)

Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)

Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)

Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)

Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)

Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)

Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)

Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)

Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)

Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)

Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)

Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)

Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)

Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)

Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)

Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)

Appendix F: Technical Notes (412-412)

Appendix G: Biographical Notes on Committee Members (413-417)

Appendix H: Additional Sources of Advice to the Committee (418-419)

Appendix I: Contents of Supplement to Volume II (420-420)

Appendix J: Preface to Volume I (421-422)

Appendix K: Contents to Volume I (423-423)

Index (424-432)